ALNY Q3 2020 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$126M+79.6% YoY

Gross Profit

$104M82.7% margin

Operating Income

-$225M-178.9% margin

Net Income

-$253M-201.3% margin

EPS (Diluted)

$-2.18

QoQ Revenue Growth

+21.1%

Cash Flow

Operating Cash Flow

-$110M

Free Cash Flow

-$123M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$3.3B

Total Liabilities

$2.1B

Stockholders' Equity

$1.2B

Cash & Equivalents

$497M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$126M	$70M	+79.6%
Gross Profit	$104M	$65M	+60.5%
Operating Income	-$225M	-$216M	-4.1%
Net Income	-$253M	-$209M	-21.5%

Revenue Segments

Product

$99M100%

Geographic Segments

UNITED STATES

$39M47%

Europe

$30M37%

Non-US Or Europe

$13M16%